Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $20 | $16 | $41 | $24 |
| Short-Term Investments | $22 | $36 | $24 | $44 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $2 | $3 | $4 |
| Total Curr. Assets | $43 | $55 | $68 | $72 |
| Property Plant & Equip (Net) | $0 | $0 | $7 | $7 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $1 |
| Total NC Assets | $0 | $0 | $7 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $43 | $55 | $75 | $80 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $2 | $2 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $5 | $6 | $5 | $6 |
| Total Curr. Liab. | $6 | $8 | $7 | $8 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $2 | $2 | $0 |
| Other Liabilities | -$1 | -$2 | -$2 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $6 | $8 | $7 | $8 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$222 | -$212 | -$189 | -$174 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $260 | $0 | $257 | $246 |
| Total Equity | $38 | -$212 | $68 | $72 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $43 | $55 | $75 | $80 |
| Net Debt | -$19 | -$16 | -$40 | -$24 |